BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SFP Alpes - ECPv6.17.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://sfp-alpes.fr
X-WR-CALDESC:Évènements pour SFP Alpes
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260915T110000
DTEND;TZID=Europe/Paris:20260915T120000
DTSTAMP:20260910T142118Z
CREATED:20260910T142118Z
LAST-MODIFIED:20260910T142118Z
UID:10000243-1789470000-1789473600@sfp-alpes.fr
SUMMARY:Thomas KISBY (Centre for Nanotechnology in Medicine\, Manchester (UK)
DESCRIPTION:Nanoscale approaches to brain tumour therapy : harnessing biology for targeted therapeutics\nRésumé : \nGlioblastoma remains one of the most challenging cancers to treat\, in part because conventional approaches struggle to selectively access and target the cells responsible for recurrence. This talk will explore how nanoscale technologies can exploit the biology of brain tumours and the brain to create new therapeutic opportunities. Using graphene oxide\, a nanomaterial with preferential interaction with tumour-associated immune cells\, I will describe how we can use this as a locally administered platform for both more localised chemotherapy and targeted tumour immunomodulation. \nI will then discuss a new approach that exploits the biological response to tumour resection itself : a transient postoperative window in which the blood–brain barrier becomes selectively\npermeable to clinically used liposomal nanomedicines. By linking the timing and biology of surgery with nanoscale drug delivery\, we have developed an approach to specifically target residual disease at the site of recurrence. Together\, these studies illustrate how understanding and exploiting biological processes can guide the design and application of nanotherapeutics for brain cancer. \n_ \nContact : anne-laure.bulin@univ-grenoble-aleps.fr
URL:https://sfp-alpes.fr/event/thomas-kisby-centre-for-nanotechnology-in-medicine-manchester-uk/
LOCATION:IAB – Salle de séminaire\, IAB Site Santé - Allée des Alpes\, La Tronche\, 38700\, France
CATEGORIES:Séminaire
ORGANIZER;CN="IAB":MAILTO:appaixfl@univ-grenoble-alpes.fr
END:VEVENT
END:VCALENDAR